2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

907. Outcomes Research: Plasma Cell Disorders: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Young Adult
PAPER

6295 Frailty alone does not preclude outpatient elranatamab step-up with dexamethasone prophylaxis in multiple myeloma

Mark R Korst, MD, Joshua Gustine, MD, MPH2, E. Bridget Kim, PharmD3, Kacthary Sanclemente, RN4, Sarah O'Neill, PharmD5, Matthew Lei, PharmD6, Christina Cioffi, RN7, Alexis Barselau8, Advait Joshi, MBBS9, Luvlee A Perry10, Kareem Mosaheb11, Andrew J. Yee, MD12, Andrew Branagan, MD, PhD13, Benjamin Robert Puliafito, MD14, Noopur S Raje, MD15, Diana D Cirstea, MD16
1 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
2 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
3 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
4 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
5 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
6 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
7 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
8 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
9 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
10 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
11 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
12 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
13 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
14 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
15 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States
16 Massachusetts General Brigham Cancer Institute, Boston, Massachusetts, United States

Introduction

Bispecific antibodies have expanded effective treatment options for relapsed/refractory multiple myeloma (R/R MM), including frail patients who historically have had limited therapeutic options because of comorbidities and treatment-related toxicity. Step-up dosing (SUD) is frequently performed inpatient because of the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), with frail patients often considered poor candidates for outpatient SUD despite limited evidence supporting frailty alone as exclusion criteria (Adegbite B et al. Blood Adv 2025; Pasvolsky O et al. Blood Cancer J 2025; Portuguese AJ et al. Blood Cancer J 2026). We evaluated acute toxicity and unplanned healthcare utilization among frail patients undergoing outpatient elranatamab step-up through the Bispecific Outpatient Safe Step-up (BOSS) program, an initiative for outpatient step-up dosing at the Mass General Brigham Cancer Institute (MGBCI).

Methods

Patients with R/R MM receiving outpatient elranatamab step-up through BOSS at the MGBCI were retrospectively analyzed. Patients were selected for BOSS using predefined criteria, including disease burden, fitness, inflammatory markers, degree of cytopenia, caregiver availability, and proximity to the treating center. Frailty was assessed using the simplified frailty scale including age, Charlson Comorbidity Index (CCI), and ECOG performance (Facon T et al. Leukemia 2019). Elranatamab SUD was administered using the BOSS pathway, which incorporates post-treatment prophylactic dexamethasone, daily monitoring by telephone call, scheduled clinician-led safety assessments, a standardized acute care pathway, and rapid access to urgent care, allowing outpatient escalation of care before hospital referral when appropriate. The primary endpoint was unplanned healthcare utilization during SUD, defined as urgent clinic visits, emergency department visits, or hospital admissions. Secondary endpoints included CRS, ICANS, and infections. Univariate logistic regression was performed to identify associations between frailty, clinical and disease characteristics, and healthcare utilization.

Results

Thirty-eight patients underwent outpatient elranatamab SUD through BOSS, including 13 frail and 25 non-frail patients. Frail patients were older (median age, 80 versus 70 years; p=0.008) and had lower functional status (ECOG performance of ≥1, 77% among frail versus 40% non-frail patients; p=0.04). Otherwise, frail and non-frail patients had similar disease characteristics and prior treatment exposure. Baseline CRP and ferritin were lower among frail patients—1.8 versus 6.3 (p=0.009), and 58 versus 132 (p=0.04), respectively. Frail patients had fewer unplanned healthcare encounters than non-frail patients (30.8% of frail patients, 72% of non-frail patients; odds ratio (OR)=0.18; p=0.02). Frail patients accounted for 18.1% of total healthcare use in the cohort (including 17.6% of total clinic visits and 22.2% of total hospital admissions). Eleven of 13 frail patients (84.6%) completed SUD dosing without being admitted to the hospital, while 9 (69.2%) of them completed SUD without an urgent clinic visit. There was one isolated emergency visit in the entire cohort, which was from a frail patient. CRS occurred numerically less frequently in frail patients than non-frail patients (23.1% vs 48%; OR=0.33; p=0.18); there were 3 instances of grade ≥2 CRS (1 event in frail; 2 events in non-frail); infection rates were comparable between frail and non-frail patients (OR=0.96, p=1.00); only one ICANS (grade 1) event occurred in a frail patient. CRS accounted for 45.8% of all unplanned encounters, whereas infection, pain, and ICANS were uncommon causes of presentation (16.7% infection, 12.5% pain, 4.2% ICANS, and 20.8% other). Approximately one third (37.5%) of unplanned encounters resulted in hospital admission, none of which necessitated ICU transfer.

Conclusions

Selected frail patients successfully completed outpatient elranatamab step-up in the BOSS program. Our findings suggest that frailty alone should not preclude outpatient bispecific initiation. Instead, patient selection should incorporate disease burden, inflammatory profile, marrow reserve, and caregiver support. Larger multi-center studies are warranted to validate risk-adapted outpatient selection strategies and refine implementation models for increasingly diverse myeloma populations.

Mark R Korst, MD: No relevant conflicts of interest to declare.